Abstract: The present invention relates to the use of analogs of thrombomodulin ("TM") that have the ability to enhance the thrombin-mediated activation of protein C but which have a significantly reduced ability to inhibit the direct procoagulant activities of thrombin, such as, for example, thrombin-mediated conversion of fibrinogen to fibrin. These analogs are useful in, for example, antithrombotic therapy. Novel proteins, nucleic acid gene sequences, pharmaceuticals and methods of inhibiting thrombotic activity are disclosed. Included are methods for increasing the circulating half life of the proteins.
Type:
Grant
Filed:
November 22, 1993
Date of Patent:
November 14, 1995
Assignee:
Schering Aktiengesellschaft
Inventors:
Charles B. Glaser, Michael J. Morser, David R. Light
Abstract: A substantially pure heterotrimeric laminin variant comprising the structure M-X-B2, wherein M is the M polypeptide of merosin; X is selected from the group consisting of the B1 chain of laminin and S-laminin; and B2 is the B2 chain of laminin.
Type:
Grant
Filed:
July 8, 1993
Date of Patent:
August 22, 1995
Assignees:
La Jolla Cancer Research Foundation, Washington University
Abstract: A method of sorting living cells based on DNA content. Mammalian sperm subpopulations enriched in X- or Y-sperm. X- and Y-enriched sperm-plasma-membrane vesicles. Substantially pure sex-associated membrane (SAM) proteins. Antibodies binding to X- or Y-SAM proteins, essentially free of antibodies binding to Y- or X-SAM proteins respectively, or to the H-Y antigen. Semen samples enriched for X- or Y-sperm. Methods for increasing the probability that offspring will be male or female comprising the step of allowing as sperm from an enriched semen sample to fertilize an ovum. Methods for increasing the probability that offspring will be male or female comprising the step of immunizing a female with X- or Y-SAM proteins. Methods of decreasing fertility comprising the step of immunizing a female with both X- and Y-sperm. Methods of increasing the probability that mammalian offspring will carry a gene for a particular sex-chromosome linked trait.
Abstract: Hexapeptides of formula (I) deriving from aglucoteicoplanin and their salts with acids and bases as well as their inner salts wherein R is hydrogen or a protecting ##STR1## group of the amino function. The products of formula (I), wherein R is hydrogen, possess antimicrobial activity in particular against coagulase-negative strains and some S. aureus and S. epidermidis strains which have low sensitivity toward teicoplanin. The hexapeptides are produced by reductive cleavage of aglucoteicoplanin with alkali metal borohydrides in the presence of a hydroalcoholic mixture as solvent.
Abstract: The present invention relates to a process for manufacturing a composition highly containing .alpha.-lactalbmin. This process comprises adjusting, to pH of 2-4 or 5 or higher, cheese whey, acid casein whey or rennet casein whey; contacting the whey with an ion exchanger, to produce an exchanger-passed solution; and then, concentrating and/or desalting the exchanger-passed solution, if necessary after the exchanger-passed solution is adjusted to a pH of 4 or lower. According to the present process, it is possible to efficiently produce a high .alpha.-lactalumin content composition at low cost and in a simple and easy manner on an industrial scale. The resultant high .alpha.-lactalumin content composition can be used for food materials and medical materials.
Abstract: A method for selectively opening abnormal brain tissue capillaries of a mammal in order to allow selective passage of both low and high molecular weight neuropharmaceutical agents into abnormal brain tissue. The method utilizes direct infusion of bradykinin into the carotid artery. The dose of bradykinin is maintained at levels which provide opening of abnormal brain tissue capillaries without opening normal brain capillaries. The method is useful for introducing a wide variety of neuropharmaceutical agents selectively to brain tumors and other abnormal brain tissue.
Abstract: The invention relates to methods for stabilizing human interferon, including pharmaceutical compositions useful in topical applications for the treatment of disorders such as Condyloma acuminata. Amine stabilizing agents such as primary aliphatic amines and anionic stabilizing agents such as lithium organo sulfates protect human interferons from degradation and provide enhanced storage stability. These stabilizing agents containing interferon can be added to appropriate pharmaceutical carriers for topical applications. The topical products also exhibit enhanced storage stability.
Abstract: Thrombin inhibitors represented by the formula ##STR1## as provided wherein A(C.dbd.O)-- is, inter alia, phenylglycyl, cyclohexylglycyl, cyclohexenylglycyl, thienylglycyl or naphthylglycyl, wherein the .alpha.-amino group is preferably substituted by alkyl e.g. methyl or an alkoxycarbonyl, cycloalkoxycarbonyl or arylkoxycarbonyl group e.g. t-butyloxycarbonyl. A(C.dbd.O)-- also represents an .alpha.-substituted acetyl group such as .alpha.-methoxyphenylacetyl; or a bicyclic group such as a tetrahydroisoquinolin-1- or 3-carbonyl group; a perhydroisoquinolin -1- or -3-carbonyl group; or a 1-amino or (substituted amino) cycloalkylcarbonyl group such as 1-aminocyclohexylcarbonyl. Also provided are a method for inhibiting the formation of blood clots in man and animals by administering a thrombin inhibitor of the above formula and pharmaceutical formulations useful in the method.
Abstract: TGF.beta. is used to increase the numbers of stem cells in a subject's peripheral blood. Then the subject's blood is drawn and the stem cells removed. After myelosuppressive therapy is administered to the subject, the stem cells are administered to the subject. An alternate method provides for TGF.beta. administration to a donor subject whose blood is drawn and from whose blood the stem cells are removed; after a recipient subject receives myelosuppressive therapy, the stem cells are administered to the recipient subject.
Abstract: A formulation suitable for inducing bone formation contains about 0.5 .mu.g to about 5 mg of transforming growth factor-.beta. and about 140 mg to about 50 g of tricalcium phosphate and excludes a bone morphogenetic cofactor. In another embodiment, the formulation contains about 0.5 .mu.g to 5 mg transforming growth factor-.beta., about 140 mg to 50 g of tricalcium phosphate particles, and an amount of amylopectin ranging from about 01:1 to 1:1 amylopectin:tricalcium phosphate.
Type:
Grant
Filed:
June 8, 1994
Date of Patent:
June 6, 1995
Inventors:
Arthur J. Ammann, Steven L. Beck, Tue H. Nguyen, Boonsri Ongpipattanakul, Christopher G. Rudman
Abstract: Fetal growth is promoted and fetal growth retardation is reduced in mammals by increasing in a maternal host during pregnancy the active concentration of IGF-1 and /or IGF-2 and/or analogues thereof. The active concentration of IGF-1 and/or IGF-2 and/or analogues thereof may be increased either by directly administering to the maternal host IGF-1 and/or IGF-2 and/or analogs thereof or by administering another compound which, upon being so administered, causes an increase in the active concentration of IGF-1 and/or IGF-2 and/or analogues thereof in the maternal host.
Type:
Grant
Filed:
February 10, 1993
Date of Patent:
May 30, 1995
Assignee:
Auckland Uniservices Limited
Inventors:
Peter D. Gluckman, Geoffrey R. Ambler, Bernhard H. Breier
Abstract: The present invention provides novel lipophilic disaccharide-dipeptide compounds. The compounds of the invention are preferably encapsulated into multilamellar liposomes, which can be formed from phosphatidyl choline and phosphatidyl glycerol. The compounds are effective in activating human monocytes with subsequent destruction of tumor cells. These compounds have acceptable toxicity in anticipated human dosages.
Type:
Grant
Filed:
April 13, 1990
Date of Patent:
May 16, 1995
Assignee:
ImmunoTherapeutics, Inc.
Inventors:
Gerald J. Vosika, Dennis A. Cornelius, John A. Bennek, Karl E. Swenson, Carl W. Gilbert
Abstract: A transparent adjusted milk whey protein is prepared by a method in which milk whey protein is purified and then the pH of a solution containing the milk whey protein is adjusted to not higher than 4 or not lower than 6. The solution may be heated to a temperature not lower than 55.degree. C. before or after adjusting the pH. Further, an adjusted milk whey product is prepared by a method in which the pH of a solution containing milk whey protein is adjusted to not higher than 4 or not lower than 6 and the solution is heated at a temperature not lower than 55.degree. C. and cooled to a temperature not higher than 10.degree. C., or a method in which the pH of a solution containing purified milk whey protein is adjusted to not higher than 4 or not lower than 6 under such a condition as salt content of the solution is 0 or not higher than 50 mM, and the solution is heated at a temperature not lower than 55.degree. C. and cooled to a temperature not higher than 10.degree. C.
Abstract: The use of TGF-.beta..sub.3 to reduce the formation of scar tissue as a result of trauma to the cornea of the eye is described. The invention is particularly directed to the use of TGF-.beta..sub.3 to reduce the formation of scar tissue in connection with ophthalmic surgical procedures involving the cornea, such as laser irradiation of the cornea. A composition containing TGF-.beta..sub.3 is applied to the site of the trauma to alter the production and composition of extracellular matrix synthesized by fibroblasts, and thereby reduce the formation of scar tissue and consequent impairment of vision.
Abstract: A method is provided for generation of bone at a site of an animal where skeletal tissue is deficient comprising administering to the animal, locally at the bone site in the presence of a source of osteogenic cells, an effective amount of a composition comprising TGF-.beta. in a pharmaceutically acceptable carrier, provided that such composition excludes a bone morphogenetic cofactor, the composition being administered in an amount effective to induce bone growth at the bone site. Also provided is a device for implantation into a site of an animal where skeletal tissue is deficient comprising a device treated with an effective amount of a composition comprising TGF-.beta. and a source of osteogenic cells in a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
November 12, 1993
Date of Patent:
April 25, 1995
Assignee:
Genentech, Inc.
Inventors:
Arthur J. Ammann, Christopher G. Rudman
Abstract: The present invention provides a liposome comprising an effective immunoadjuvant amount of a lymphokine such as IL-2. Also provided is an effective antineoplastic amount of IL-2 liposomes in combination with adoptively transferred cells stimulated with anti-CD3 monoclonal antibody plus IL-2.
Type:
Grant
Filed:
October 28, 1992
Date of Patent:
April 25, 1995
Assignee:
The Regents of The University of Minnesota
Inventors:
Peter M. Anderson, Arnold S. Leonard, Augusto C. Ochoa, Cynthia Loeffler
Abstract: The invention relates to a process for purifying human von Willebrand factor from a cryoprecipitated plasma fraction, which comprises a combination of three chromatographic separation steps. The first chromatographic separation step comprises contacting a cryoprecipitated fraction with a large-pore vinyl polymer resin having DEAE group. The effluent from this separation step is again contacted with a large pore vinyl polymer resin having DEAE groups in the second chromatographic step. In the third chromatographic separation step, the effluent from the second step is subjected to affinity chromatography by contacting with gelatin-Sepharose. The concentrate obtained has very high specific activity and a high percentage of high molecular weight multimers. The concentrate is intended, in particular, for therapeutic use.
Type:
Grant
Filed:
March 6, 1992
Date of Patent:
April 18, 1995
Assignee:
Centre Regional de Transfusion Sanguine de Lille
Abstract: Bone morphogenetic proteins -2 and -3 (BMPs -2 and -3) work in synergistic combination with TGF-.beta.z to provide compositions with increased osteogenic activity. Methods of treating bone defects, inducing bone growth and increasing bone marrow cell production using these compositions are also disclosed.
Type:
Grant
Filed:
September 15, 1993
Date of Patent:
February 28, 1995
Assignee:
Celtrix Pharmaceuticals, Inc.
Inventors:
Hanne Bentz, Andrea Y. Thompson, Rosa Armstrong, David M. Rosen
Abstract: Stroma-free hemoglobin cross-linked with reagents that mimic 2,3-diphosphoglycerate and transform stroma-free hemoglobin into a physiologically competent oxygen carrier which is retained in vivo for adequate periods of time, and thus can be used in fluids for transporting oxygen is described.